Yam Code

New Paste Browse

https://www.selleckchem.com/products/Rapamycin.html Rationale & objective Sodium glucose cotransporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease and prevent heart failure events. However, SGLT2 inhibitors may increase the risk of acute kidney injury (AKI). Our objective was to assess whether SGLT2 inhibitor use, compared to all other glucose lowering drugs (oGLD), is associated with increased rates of AKI. Study design Retrospective cohort study. Setting & participants Adults in Manitoba, Canada with type 2 diabetes mellitus (T2DM) followed from June 2014 until March 2017. Exposures Initial SGLT2 inhibitor or oGLD use ascertained through a province-wide outpatient prescription database. Outcome The primary outcome was incident AKI, identified either by a rise in serum creatinine and/or hospital discharge codes for AKI while taking glucose lowering drugs (on-treatment approach). Analytical approach A propensity score analysis was used to assemble groups of incident users of SGLT2 inhibitors and a 11 matched set of users of oGLD. The rate of AKI was compared across matched groups using cause-specific hazards models. Sensitivity analyses considered exposure to be constant throughout follow-up after initiation of the drug (intention-to-treat approach) or incorporated recurrent exposures (new user design). Results Comparing 4,778 incident users of SGLT2 inhibitor to 4,778 incident users of oGLD, there were no differences observed in the primary outcome (HR 0.64, 95% CI 0.40 - 1.03, p = 0.064) using an on-treatment approach. In neither set of sensitivity analyses were SGLT2 inhibitors associated with an increased risk of AKI. Limitations Drug choice may have been related to AKI risk, laboratory data were obtained from clinical care, and changes in adverse event reporting may have followed the FDA warning. There were insufficient data to compare individual SGLT2 inhibitors. Conclusions Compared to oGLD, SGLT2 inhibitors were not observed to be ass

Paste Settings

Paste Title : [Optional]

Paste Folder : [Optional]

Syntax Highlighting : [Optional]

Paste Expiration : [Optional]

Paste Status : [Optional]

Password : [Optional]

Description: [Optional]

Tags: [Optional]

Encrypt Paste (?)

You are currently not logged in, this means you can not edit or delete anything you paste. Sign Up or Login

Paste Settings

Site Languages